Concepts in genetic medicine

TL;DR: It is shown that RNAi can be applied to inhibit production of HBV replicative intermediates in cell culture and in immunocompetent and immunodeficient mice transfected with an HBV plasmid, showing that such an approach could be useful in the treatment of viral diseases.

TL;DR: In this paper, the authors reviewed T-cell products screened for replication-competent lentivirus (RCL) using methodology developed in the National Gene Vector Biorepository.

TL;DR: Advances in the technological approaches and methods for ex vivo manipulation have led to T lymphocytes endowed with enhanced potency and unique functions, with promise as the new generation of infused therapeutics.

TL;DR: In this article, the authors applied s-galactosidase expressing equine infectious anaemia virus (EIAV) pseudotyped with VSV-G by single or combined injection via different routes to the MF1 mouse fetus on day 15 of gestation and describe substantial gene delivery to the musculature.

TL;DR: The effects of macrophage depletion in combination with temporary blockade of CD40 ligation on E1-deleted adenovirus vector-mediated gene transfer is examined to demonstrate that this treatment is transient and antigen-specific.

TL;DR: A recombinant peptide-based gene delivery vector that targets nerve growth factor (NGF) receptors that activated the high-affinity NGF receptor, TrkA, and displayed NGF-like bioactivity by promoting neurite outgrowth and cell survival after serum deprivation.

TL;DR: RSV40 vectors effectively deliver HIV-1-inhibitory RNAs using either constitutive or conditional pol II promoters, or using a pol III promoter, and the versatility of this gene delivery system may prove to be useful in anti-HIV-1 therapeutics.

TL;DR: The treatment of HIV-related lymphomas is evolving in the era of HAART and standard-dose chemotherapy and dose-intensive therapies appear to be feasible.